Therapeutic Area

Rheumatology

Therapeutic area intelligence for Rheumatology with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 0
Companies: 1

Companies

KSHB Biopharma →

Assets

KSHB002 →

Recent signals(2)

ClinicalJune 19, 2026

Study on Cardiac Rehabilitation in Hypertensive Rheumatoid Arthritis Patients Initiated

A clinical trial is underway to assess the effects of a 6-week cardiac rehabilitation program in hypertensive patients with controlled rheumatoid arthritis.

ClinicalJune 17, 2026

KSHB002 Trial Shows Equivalence to ORENCIA in PK, Safety, and Immunogenicity for RA

The trial aims to establish the pharmacokinetic equivalence, safety, and immunogenicity of KSHB002 compared to ORENCIA in healthy subjects.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Rheumatoid Arthritis →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.